A Phase III, Randomized, Open-label, Clinical Trial to Compare Pembrolizumab With Brentuximab Vedotin in Subjects With Relapsed or Refractory Classical Hodgkin Lymphoma
The purpose of this study is to evaluate pembrolizumab (MK-3475) in the treatment of
participants with relapsed or refractory Classical Hodgkin Lymphoma. Participants will be
randomized to receive either pembrolizumab or brentuximab vedotin for up to 35 three-week
cycles of treatment.
The primary hypotheses of this study are that treatment with pembrolizumab prolongs
Progression Free Survival (PFS) and Overall Survival (OS) in participants with relapsed or
refractory Classical Hodgkin Lymphoma compared to treatment with brentuximab vedotin.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society